| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
Breckpoint is dedicated to helping brokers and employers build alternative risk solutions outside of the traditional insurance providers. For employers seeking an alternative to fully-insured group benefit plans or self-insured groups for workers compensation, Breckpoint empowers groups to take advantage of the transparency, control, and underwriting profits generated by high performing self-funded plans. - Self funded benefit administration plans - Self-insured group administration for workers compensation - Captive Management - Risk Management services We believe in Leading Together. This is the essence of Breckpoint. We are here with you through every step of this benefit journey. Your Breckpoint team provides the stellar service you deserve and we look forward to helping you manage your alternative risk programs.
Carrington Fox is a boutique executive search firm founded in 2001, based in New York City. The company specializes in human capital solutions for global financial markets, focusing on executive and contingent search mandates. With a team of approximately 25 to 50 employees, Carrington Fox generates an estimated annual revenue between $5 million and $25 million. The firm serves clients in investment banking, private equity, hedge funds, tax, accounting, and quantitative analytics. They emphasize long-term partnerships, aiming to understand client needs and candidate aspirations deeply. Carrington Fox is known for its niche expertise in front-office financial roles and quantitative disciplines, providing tailored recruitment processes with a commitment to confidentiality and efficiency.
Ayesa is a global provider of technology and engineering services with more than 11500 employees in twenty-three countries across Europe, Latin America, Africa and Asia. The company develops and implements digital solutions for the private and public sector and uses the latest technology to provide cutting-edge infrastructure design and supervision services. To do this, it has certified experts covering more than 70 different disciplines in utilities and energy; the public sector; banking and insurance; water and the environment, transportation; aeronautics and defence; and construction. As a company that is driven by people and innovation, its business approach is underpinned by talent.